The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestrationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study asked how two human-targeted drugs disturb whole gut microbiomes and by what mechanism. Researchers incubated fresh human faecal samples ex vivo with entacapone (a Parkinson's disease treatment) or loxapine succinate (a schizophrenia treatment) at physiologically relevant colon concentrations. They combined quantitative microbiome profiling, 16S amplicon and long-read metagenomic sequencing, heavy-water single-cell activity imaging, and chemical imaging of drug uptake. They then tested whether iron chelation drove the effects, using iron rescue experiments and siderophore mutants.
Who was studied?
This was an ex vivo human faecal study, not a clinical trial. Faecal samples came from nine healthy adults (three men and six women aged 22 to 39) who had taken no antibiotics in the prior three months. Most experiments pooled samples from six of these donors, incubated anaerobically at 37 degrees Celsius. Entacapone was tested at an estimated colon concentration of 1,965 micromolar. Some findings were confirmed in pure bacterial cultures and Escherichia coli mutants.
What were the most important findings?
High-dose entacapone had a much stronger effect than loxapine. It significantly altered 29.4% of all bacterial amplicon variants after 24 hours and reduced total microbial cell numbers, while loxapine altered 11.8%. Entacapone's catechol group complexed iron, and this activity was not affected by nitroreduction. Adding iron reversed the growth inhibition across most affected taxa. Iron starvation selected for siderophore-producing Enterobacteriaceae, chiefly an Escherichia coli strain whose genome encodes 14 resistance and virulence genes plus enterobactin machinery.
What are the greatest implications of this study?
The work identifies metal sequestration as a mechanism by which a human-targeted drug disturbs the gut microbiome. Entacapone depletes iron, a limiting nutrient, favouring potentially harmful iron-scavenging bacteria. This may relate to reported increases in Enterobacteriaceae and diarrhoea in some Parkinson's patients taking entacapone. The authors propose that delivering iron to the colon could help preserve microbiome balance. These are short-term ex vivo results from healthy donors, so long-term patient cohorts are still needed.